JOMPAC
Journal of Medicine and Palliative Care

Journal of Medicine and Palliative Care (JOMPAC) is an open access scientific journal with independent, unbiased, and double-blind review under international guidelines. The purpose of JOMPAC is to contribute to the literature by publishing articles on health sciences and medicine.

eISSN: 2717-7505
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
The use of intralesional epidermal growth factor in the treatment of diabetic foot ulcers
Abstract
Aims: The mitogenic and cell protective effects of epidemal growth factor (EGF) in wound healing stimulate the growth, re-covering the surface of the wound area. In this research we tried to elucidate the effectiveness of intradermal EGF application on wound healing in diabetic foot ulcers regarding the fact that EGF can accelerate the formation of skin cover layer on the infected surface, even in relatively ischemic cases.
Methods: The data of 68 patients who applied to our institution’s orthopedics and wound care outpatient clinic with the diagnosis of diabetic foot ulcer, who underwent wound care, debridement and follow-up were retrospectively analyzed. All of the patients included in this study were classified as Wagner Stage III and Stage IV diabetic foot ulcers and were followed up with standard wound care. EGF application was initiated if there was not enough bleeding on the wound borders and defect floor after debridement.
Results: The rate of patients with 50% or more granulation in the second week of treatment in the groups was 35.7% (n=10) in the standard treatment group, it was 60% (n=24) in the EGF group (p<0.05). Complete granulation rates at the fourth week of treatment in patients who did not show complete granulation in the second week of treatment was 30.8% (n=8) in the standard treatment and 61.1% (n=22) in the EGF treatment (p<0.05). Similarly, in patients who did not show complete granulation in the fourth week of treatment, complete granulation rates at the sixth week of treatment was found to be 44.4% (n=8) in standard treatment and 85.7% (n=12) in EGF treatment (p<0.05).
Conclusion: According to the results of this study, intradermal EGF application in diabetic foot ulcers may positively affect wound healing by accelerating the formation of a skin cover layer.

Keywords : Diabetic foot ulcer, EGF, epidermal growth factor, diabetic ulcer, wound care

Download Article


1. Fernandez-Montequin JI, Valenzuela-Silva CM, Gonzalez DiazO, et al. For the Cuban Diabetic Foot Study Group. Intra-lesional injections of recombinant human epidermal growthfactor promote granulation and healing in advanced diabeticfoot ulcers: multicenter, randomised, placebo-controlled, double-blind study. Int Wound J. 2009;6:432-443
2. Berlanga-Acosta J. Diabetic lower extremity wounds: the rationalefor growth factors-based infiltration treatment. Int Wound J.2011;8(6):612-620. doi:10.1111/j.1742-481X.2011.00840.x
3. Valenzuela-Silva CM, Tuero-Iglesias &Aacute;D, Garc&iacute;a-Iglesias E, et al.Granulation response and partial wound closure predict healingin clinical trials on advanced diabetes foot ulcers treated withrecombinant human epidermal growth factor. Diabetes Care.2013;36(2):210-215. doi:10.2337/dc12-1323
4. Tsang MW, Wong WK, Hung CS, et al. Human epidermal growthfactor enhances healing of diabetic foot ulcers. Diabetes Care.2003;26(6):1856-1861. doi:10.2337/diacare.26.6.1856
5. Gomez-Villa R, Aguilar-Rebolledo F, Lozano-Platonoff A, et al.Efficacy of intralesional recombinant human epidermal growthfactor in diabetic foot ulcers in Mexican patients: a randomizeddouble-blinded controlled trial. Wound Repair Regen. 2014;22(4):497-503. doi:10.1111/wrr.12187
6. Singla S, Garg R, Kumar A, Gill C. Efficacy of topical applicationof beta urogastrone (recombinant human epidermal growthfactor) in Wagner&rsquo;s grade 1 and 2 diabetic foot ulcers: comparativeanalysis of 50 patients. J Nat Sci Biol Med. 2014;5(2):273-277.doi:10.4103/0976-9668.136160
7. Park KH, Han SH, Hong JP, et al. Topical epidermal growth factorspray for the treatment of chronic diabetic foot ulcers: a phaseIII multicenter, double-blind, randomized, placebo-controlledtrial. Diabetes Res Clin Pract. 2018;142:335-344. doi:10.1016/j.diabres.2018.06.002
8. Yang S, Geng Z, Ma K, Sun X, Fu X. Efficacy of topical recombinanthuman epidermal growth factor for treatment of diabetic footulcer: a systematic review and meta-analysis. Int J Low ExtremWounds. 2016;15(2):120-125. doi:10.1177/1534734616645444
9. Yang S, Geng Z, Ma K, Sun X, Fu X. Efficacy of topical recombinanthuman epidermal growth factor for treatment of diabetic footulcer: a systematic review and meta-analysis. Int J Low ExtremWounds. 2016;15(2):120-125. doi:10.1177/1534734616645444
10. Basu S, Yoffe P, Hills N, Lustig RH. The relationship of sugar topopulation-level diabetes prevalence: an econometric analysisof repeated cross-sectional data. PLoS One. 2013;8(2):e57873.doi:10.1371/journal.pone.0057873
11. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers inpatients with diabetes. JAMA. 2005;293(2):217-228. doi:10.1001/jama.293.2.217
12. Moxey PW, Gogalniceanu P, Hinchliffe RJ, et al. Lower extremityamputations--a review of global variability in incidence. DiabetMed. 2011;28(10):1144-1153. doi:10.1111/j.1464-5491.2011.03279.x
13. Bakker K, van Houtum WH, Riley PC. 2005: The InternationalDiabetes Federation focuses on the diabetic foot. Curr Diab Rep.2005;5(6):436-440. doi:10.1007/s11892-005-0051-y
14. Steed DL, Attinger C, Colaizzi T, et al. Guidelines for the treatmentof diabetic ulcers. Wound Repair Regen. 2006;14(6):680-692.doi:10.1111/j.1524-475X.2006.00176.x
15. Buchberger B, Follmann M, Freyer D, Huppertz H, EhmA, Wasem J. The evidence for the use of growth factors andactive skin substitutes for the treatment of non-infecteddiabetic foot ulcers (DFU): a health technology assessment(HTA). Exp Clin Endocrinol Diabetes. 2011;119(8):472-479.doi:10.1055/s-0031-1279713
16. Agudelo-Su&aacute;rez AA, Ruiz-Cantero MT, Gonz&aacute;lez-Zapata LI,Restrepo-Medrano JC, Ortiz-Barreda GM. The parliamentary politicalagenda: a tool for policy analysis of diabetes priorities in Spain. GacSanit. 2012;26(6):554-559. doi:10.1016/j.gaceta.2012.03.002
17. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas:global estimates of the prevalence of diabetes for 2011 and 2030.Diabet Res Clin Pract. 2011;94(3):311-321.
18. Berlanga-Acosta J, Fern&aacute;ndez-Montequ&iacute;n J, Vald&eacute;s-P&eacute;rez C, etal. Diabetic foot ulcers and epidermal growth factor: revisitingthe local delivery route for a successful outcome. Biomed Res Int.2017;2017:2923759. doi:10.1155/2017/2923759
19. Singla S, Singla S, Kumar A, Singla M. Role of epidermalgrowth factor in healing of diabetic foot ulcers. Indian J Surg.2012;74(6):451-455. doi:10.1007/s12262-012-0447-2
20. Fern&aacute;ndez-Montequ&iacute;n JI, Infante-Cristi&aacute; E, Valenzuela-Silva C,et al. Intralesional injections of Citoprot-P (recombinant humanepidermal growth factor) in advanced diabetic foot ulcers withrisk of amputation. Int Wound J. 2007;4(4):333-343. doi:10.1111/j.1742-481X.2007.00344.x
21. Fern&aacute;ndez-Montequ&iacute;n JI, Betancourt BY, Leyva-Gonzalez G,et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic footulcer: treatment up to complete wound closure. Int Wound J.2009;6(1):67-72. doi:10.1111/j.1742-481X.2008.00561.x
22. Vel&aacute;zquez W, Valles A, Curbelo W. Impacto del Heberprot-Pen el tratamiento de las &uacute;lceras del pie diab&eacute;tico. Biotecnolog&iacute;aAplicada. 2010;27(2):136-141.
23. Yera-Alos IB, Alonso-Carbonell L, Valenzuela-Silva CM, etal. Active post-marketing surveillance of the intralesionaladministration of human recombinant epidermal growth factorin diabetic foot ulcers. BMC Pharmacol Toxicol. 2013;14:44.doi:10.1186/2050-6511-14-44
24. Gonz&aacute;lez Acosta S, Cala&ntilde;a Gonz&aacute;lez Posada B, Marrero Rodr&iacute;guezI, L&oacute;pez Fern&aacute;ndez R. Evoluci&oacute;n cl&iacute;nica del tratamiento en el piediab&eacute;tico con Heberprot-P o con el m&eacute;todo convencional. RevCubana Angiolog&iacute;a y Cirug&iacute;a Vascular. 2011;11(2):11.
25. Berlanga J, Fern&aacute;ndez JI, L&oacute;pez E, et al. Heberprot-P: a novelproduct for treating advanced diabetic foot ulcer. MEDICC Rev.2013;15(1):11-15. doi:10.37757/MR2013V15.N1.4
26. Valenzuela-Silva CM, Tuero-Iglesias &Aacute;D, Garc&iacute;a-Iglesias E, et al.Granulation response and partial wound closure predict healingin clinical trials on advanced diabetes foot ulcers treated withrecombinant human epidermal growth factor. Diabetes Care.2013;36(2):210-215. doi:10.2337/dc12-1323
27. Gomez-Villa R, Aguilar-Rebolledo F, Lozano-Platonoff A, et al.Efficacy of intralesional recombinant human epidermal growthfactor in diabetic foot ulcers in Mexican patients: a randomizeddouble-blinded controlled trial. Wound Repair Regen.2014;22(4):497-503. doi:10.1111/wrr.12187
28. Acosta JB, Savigne W, Valdez C, et al. Epidermal growth factorintralesional infiltrations can prevent amputation in patients withadvanced diabetic foot wounds. Int Wound J. 2006;3(3):232-239.doi:10.1111/j.1742-481X.2006.00237.x
Article available in :
Volume 4, Issue 6, 2023
Page : 607-612
https://doi.org/10.47582/jompac.1350351
Article Information
Received : 26 Ağu 2023
Accepted : 04 Kas 2023
Published : 31 Ara 2023
Corresponding Author :

Burhan Kurtuluş: Department of Orthopedics and Traumatology, Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital, University of Health Sciences, Ankara, Turkey

[email protected]
Citation : Kurtuluş B, Aydın E. The use of intralesional epidermal growth factor in the treatment of diabetic foot ulcers. J Med Palliat Care. 2023;4(6):607-612.

Read: 35
Cited: 0
Download : 32
_Footer